Trials / Completed
CompletedNCT00331864
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
A Phase IIIb, Open-label, Multi-center 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of Ranibizumab (0.3 mg and/or 0.5 mg) in Patients With Subfoveal Choroidal Neovasculariza-tion Secondary to Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 531 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A. This study will assess the safety and efficacy of ranibizumab administered on an as-needed dosing regimen in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2006-05-31
- Last updated
- 2011-02-18
- Results posted
- 2011-01-04
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00331864. Inclusion in this directory is not an endorsement.